News

Hibiscus BioVentures Partners with the Barbara Ann Karmanos Cancer Institute to Advance Translational Cancer Research

ROCKVILLE, Md.–(BUSINESS WIRE)– Hibiscus BioVentures, a firm committed to building patient-focused companies around transformative technologies, today announced it has entered into a partnership agreement with the Detroit-based Barbara Ann Karmanos Cancer Institute   (Karmanos). This partnership between Hibiscus’ venture studio, Hibiscus BioTechnology, and Karmanos seeks to leverage the combined resources of the two organizations to develop innovative therapeutics for the treatment of cancer. Karmanos is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the country.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105005389/en/

“We are excited to advance this patient-centric approach by leveraging the highly-respected development resources at Karmanos,” said Chris Jeffers, CEO of Hibiscus BioTechnology. “As translational and clinical research partners, this collaboration is focused on combining programs, capabilities and infrastructure from Hibiscus Biotechnology’s Studio Companies with Karmanos’ vast clinical research and development resources to advance cancer therapies and address unmet patient needs.”

Hibiscus BioTechnology Studio Companies each have financial and executive guidance and operating support to advance a broad range of science and technology development programs and address unmet patient needs. The collaboration with Karmanos will bring emerging Hibiscus BioTechnology Studio Companies valuable clinical resources, including laboratory and research access, scientific and thought leadership, clinical development strategy and access to the robust network of Karmanos hospitals to more rapidly advance cancer care.

“Working with emerging companies to bring innovation into the clinic is critical to help drive new cancer therapies closer to patients,” said Elisabeth Heath, MD, FACP, associate center director of Translational Sciences and leader of the Genitourinary Oncology Multidisciplinary Team at Wayne State University and Barbara Ann Karmanos Cancer Institute. “We believe the combined resources and mission that Karmanos and Hibiscus share will bring new hope and new tools to cancer treatment.

Read more here.

Recent News

08/04/2026

Capra advances domestic manufacturing of essential medicines with continued HHS support

Capra Biosciences, Inc., a biomanufacturing company leveraging modular, continuous bioreactor technology to enable flexible, cost-competitive domestic production of pharmaceutical ingredients, today announced continued progress under its project agreement with the Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS). The additional investment brings Capra’s total ASPR

07/30/2026

Governor Spanberger Announces $2.4 Million in Grants for Virginia’s Biomedical Innovation Ecosystem

Governor Abigail Spanberger today announced a $2.4 million investment in Virginia’s life sciences ecosystem through Virginia Catalyst’s highly competitive grant program. Virginia Catalyst was founded in 2013 as Virginia’s research consortium through the efforts of the Virginia General Assembly and five of Virginia’s premiere research institutions. These non-dilutive grants — funding that does not require

07/29/2026

Slone Partners Names Sona Stroud and Kim Wilson as Senior Partners

Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, today announced the appointments of Sona Stroud and Kim Wilson as Senior Partners. Stroud has been promoted to the role following nearly 15 years with the firm, while Wilson returns to the organization, further strengthening its leadership team with nearly 17 years